Cerenis Therapeutics is currently pursuing the clinical development of CER-001, an HDL mimetic, as part of a phase II study in post Acute Coronary Syndrome (post-ACS) patients, CARAT, and a phase III study for FPHA (Familial Primary Hypoalphalipoproteinemia
, an HDL deficiency due to a genetic defect which is an orphan disease), TANGO.
for myocardial infarction and aortic valve stenosis (11, 46, 47) LDL cholesterol Genetic abetalipoproteinemia Apolipoprotein B HDL cholesterol Genetic hypoalphalipoproteinemia
Corticosteroid therapy increases HDL-cholesterol concentrations in patients with active sarcoidosis and hypoalphalipoproteinemia
2007) Familial hypercholesterolemia associated with severe hypoalphalipoproteinemia
in a Moroccan family.
Among the clinical entities considered to increase CMR are type 2 diabetes, familial combined hyperlipidemia, familial hypoalphalipoproteinemia
, and polycystic ovary syndrome.
is a common finding in patients with premature CAD (present in about 5% of these patients).
is a relatively uncommon familial disorder with low HDL-C levels and generally normal LDL-C and triglyceride levels.
Apolipoprotein A-I gene polymorphism associated with premature coronary artery disease and familial hypoalphalipoproteinemia
Concentrations of apolipoprotein A-I-containing particles in patients with hypoalphalipoproteinemia
Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia
and kidney hypercatabolism of apoA-I.
Apo A-IMALLORCA impairs LCAT activation and induces dominant familial hypoalphalipoproteinemia
Postprandial lipoprotein(a) response to a single meal containing either saturated or omega-3 polyunsaturated fatty acids in subjects with hypoalphalipoproteinemia